Developer docs
API playgroundTry for free, no card

Search company profiles

eXoZymes

Full company profile

uuid0000bla

Namestring
eXoZymes
Legal namestring
eXoZymes Inc.
Websiteurl
exozymes.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

eXoZymes (NASDAQ: EXOZ) is a pre-revenue biotechnology company that has built an AI-enhanced, cell-free biomanufacturing platform for producing complex natural compounds that are rare, unscalable, or economically inaccessible through conventional means. The company's core technology centers on "exozymes" — enzymes engineered through AI and bioengineering to operate in bioreactors without living cells, eliminating the scaling bottleneck that has constrained traditional synthetic biology. The platform was demonstrated at 100-liter pilot scale in March 2026 with partner Cayman Chemical, producing 535 grams of pharma-grade NCT (N-trans-caffeoyltyramine) at 99.6% purity and 99% feedstock conversion efficiency, achieving a 100x scale-up from initial 1-liter lab work.

The company's product portfolio is organized around multiple commercialization paths from this shared technology core. Flagship product NCT is positioned for both over-the-counter metabolic wellness (through wholly-owned subsidiary NCTx, focused on gut and liver health) and pharmaceutical development of analogs targeting metabolic diseases. Additional pipeline assets include non-intoxicating cannabinoids for therapeutic applications and santalene for the fragrance market. Supporting technology includes the BioClick enzyme engineering platform backed by a $300K NIH grant. The company was founded in 2019 as Invizyne Technologies, completed its $15 million NASDAQ IPO in November 2024, rebranded to eXoZymes in February 2025, and is a portfolio company of MDB Capital Holdings with an estimated valuation of approximately $30 million as of Q4 2025.

The business model is built on technology licensing and royalty arrangements with pharmaceutical and nutraceutical companies, supplemented by contract manufacturing partnerships (e.g., Cayman Chemical) and direct commercialization through NCTx. Go-to-market is enterprise-focused, led by a Chief Commercial Officer appointed in April 2025, with distribution through direct partnerships and contract manufacturer networks. Revenue has not yet commenced; FY2025 financials show operating expenses of $9.72 million against a $9.16 million net loss, with cash reserves of $3.04 million at year-end 2025 replenished by a $5.95 million public offering in June 2026.

Short descriptiontext

eXoZymes is a pre-revenue, NASDAQ-listed biotechnology company that uses AI-engineered cell-free exozymes to sustainably biomanufacture rare natural compounds, serving pharmaceutical, nutraceutical, and specialty chemical markets through its Exozymes Platform and NCTx subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMonrovia, United States
HQ citystring
Monrovia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell-free biomanufacturing, enzyme engineering platform, biocatalytic production, metabolic health compounds, natural product manufacturing
Industry2 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYIMAMALAB
Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids)
NAICS code1 code
  • Other Basic Organic Chemical Manufacturing32519
SIC code1 code
  • Industrial Organic Chemicals2860
Product category
Cell-free Biomanufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Pre-revenue company with business model focused on licensing its cell-free biomanufacturing platform technology to pharmaceutical, nutraceutical, and specialty chemical companies. Revenue expected through technology licensing and royalty arrangements.

stocktitan.net
2Product Commercialization
TypeOne Time License
Description

Direct commercialization of high-value natural products including NCT (N-trans-caffeoyltyramine) and non-intoxicating cannabinoids. Company has launched subsidiary NCTx to commercialize NCT for gut and liver health applications.

pharmiweb.com
3Contract Manufacturing Services
TypeProfessional Services
Description

Potential revenue from providing biomanufacturing services using its platform, demonstrated through successful pilot runs with partner Cayman Chemical producing pharma-grade NCT.

nasdaq.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NCTx
Description

Subsidiary focused on gut and liver health products utilizing N-trans-caffeoyltyramine (NCT)

exozymes.com
+2 more records
Core offering1 text field

eXoZymes operates a proprietary cell-free biomanufacturing platform that uses engineered exozymes—cell-free enzyme systems designed with the aid of its AI-driven BioClick tool—to manufacture rare, high-value natural compounds at commercial scale. The company's first commercial focus is NCT (N-trans-caffeoyltyramine), a metabolic-health compound sold through its NCTx subsidiary, with a broader pipeline spanning non-intoxicating cannabinoids, santalene, and other specialty molecules for pharmaceutical, nutraceutical, and specialty-chemical buyers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99% feedstock conversion efficiency at 100-liter pilot scale
+3 more records
Product overview1 text field

eXoZymes is an AI-enhanced, cell-free biomanufacturing platform company (formerly Invizyne Technologies). The company offers a unified platform of exozymes (AI-engineered enzymes operating outside living cells) that transforms rare, unscalable, or economically inaccessible chemistry into predictable, high-purity production. The product portfolio centers on the core Exozymes Platform for cell-free biomanufacturing, with flagship product NCT (N-trans-caffeoyltyramine) offered in both over-the-counter wellness and pharmaceutical formulations, supported by the NCTx subsidiary. Additional products include non-intoxicating cannabinoids and santalene in the pipeline, plus the BioClick enzyme engineering technology. The platform collapses development timelines, lowers capital intensity, and unlocks multiple commercialization paths across pharmaceutical, wellness, and industrial markets.

Product and service6 records
1Exozymes Biomanufacturing Platform
CategoryCell-free Biomanufacturing Platform
Description

The company's core cell-free biomanufacturing platform that uses engineered exozymes and the AI-driven BioClick design tool to produce rare, high-value natural compounds for pharmaceutical, nutraceutical, and specialty-chemical customers.

2NCT (N-trans-caffeoyltyramine)
CategoryMetabolic Health Ingredient / API
Description

The company's flagship high-purity natural compound (N-trans-caffeoyltyramine) produced via the exozymes platform and positioned for metabolic-health applications, sold to nutraceutical and pharmaceutical customers.

3NCTx (Gut/Liver Health Brand)
CategoryNutraceutical Brand
Description

Specialty subsidiary brand through which eXoZymes markets NCT-based ingredients and formulations for gut-health and liver-health nutraceutical products.

4Non-intoxicating Cannabinoids (Pipeline)
CategorySpecialty Bioactives
Description

Pipeline of non-intoxicating cannabinoid molecules manufactured using the exozymes platform for pharmaceutical, wellness, and consumer-health buyers.

5Santalene (Pipeline)
CategorySpecialty Chemicals / Fragrance
Description

Cell-free produced santalene, a valuable natural aroma chemical traditionally constrained by sandalwood supply, targeted at fragrance and flavor customers.

6BioClick (Enzyme Engineering Platform)
CategoryEnzyme Engineering Technology
Description

AI-enhanced enzyme engineering platform that designs and optimizes exozymes for the company's cell-free biomanufacturing processes, accelerating the design–build–test cycle for new biocatalysts.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

Three-year collaboration (2023-2026) with Shell and U.S. Department of Energy's National Laboratory of the Rockies. Program provided technical guidance and nondilutive funding to advance eXoZymes' cell-free biomanufacturing platform toward commercial viability. Collaboration helped evaluate separation approaches and conduct technoeconomic and lifecycle analysis modeling. Company graduated from the program in 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Independent partner Cayman Chemical successfully validated eXoZymes' cell-free biomanufacturing technology at pilot scale, scaling from 1-liter to 100-liter production run. Produced over 500 grams of pharma-grade NCT at 99.6% purity with 99% feedstock conversion. This was the first end-to-end run of eXoZymes' exozyme-based biomanufacturing process by a third party, demonstrating protocol transferability and operational robustness.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-10-14
Description

Partnership with B2i Digital to spotlight the company's cell-free, AI-guided enzyme platform for scalable biomanufacturing. B2i Digital provides marketing and visibility services to highlight the company's technology and commercial opportunities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-30
Description

Two senior eXoZymes leaders elected to key governance roles within BioMADE, a federal manufacturing innovation institute focused on bioindustrial manufacturing. These appointments highlight eXoZymes' influence in advancing cell-free biomanufacturing and shaping the industry's future direction.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-26
Description

Selected as core industry partner in $9.2 million NSF-funded project led by Georgia Tech aimed at advancing modular cell-free biomanufacturing. Company developing cell-free ATP-generating module and production module for santalene. Supports creation of sustainable chemical production systems.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Codexis engineers high-performance enzymes for pharmaceutical and sustainable chemistry applications. Most directly comparable peer given shared focus on AI/ML-guided enzyme engineering for complex molecule manufacturing and licensing-driven business model.

TypeDirect peer
Description

DMC develops cell-free biomanufacturing processes using engineered enzyme cascades to produce chemicals and specialty products. Closely matches eXoZymes' core architectural choice (cell-free over cell-based).

TypeDirect peer
Description

Bota Bio uses synthetic biology and enzyme engineering to manufacture sustainable ingredients and chemicals. Shares the AI-guided enzyme platform approach for producing high-value molecules at scale.

TypeDirect peer
Description

Arzeda uses AI-driven protein design to engineer enzymes for chemical and pharmaceutical manufacturing. Comparable on the AI+enzyme engineering intersection and specialty chemical pipeline focus.

TypeDirect peer
Description

LanzaTech operates a biomanufacturing platform converting waste gases into fuels and chemicals via engineered microbes. Adjacent on biomanufacturing platform economics and sustainability-driven specialty chemicals.

TypeBroad incumbent
Description

Ginkgo operates a large-scale synthetic biology platform serving pharmaceutical, industrial, and agricultural customers. While cell-based rather than cell-free, it competes for the same biomanufacturing platform customer mindshare and licensing budgets.

TypeBroad incumbent
Description

Novonesis is a global enzyme and microbial solutions leader across industrial, food, and health markets. Represents the incumbent enzyme platform incumbent against which any newer platform like eXoZymes must compete for commercial partnerships.

TypeEmerging player
Description

Twist Bioscience provides synthetic DNA and broader synthetic biology tools, increasingly moving into biopharma and synthetic biology-enabled product discovery. Comparable on the AI+synbio frontier and pipeline of novel molecules.

9Zymergen (Ginkgo)
TypeEmerging player
Description

Now part of Ginkgo, Zymergen historically combined automation, ML, and synthetic biology for specialty chemical and materials applications. Represents the historical template of a SynBio platform company attempting specialty chemical commercialization.

TypeEmerging player
Description

SyntheticGestalt applies AI to enzyme and pathway design for industrial biotechnology customers. Closely matches eXoZymes' positioning at the intersection of generative AI, enzyme engineering, and biomanufacturing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

eXoZymes

Cell-free Biomanufacturingexozymes.com

eXoZymes is a pre-revenue, NASDAQ-listed biotechnology company that uses AI-engineered cell-free exozymes to sustainably biomanufacture rare natural compounds, serving pharmaceutical, nutraceutical, and specialty chemical markets through its Exozymes Platform and NCTx subsidiary.

What eXoZymes does

eXoZymes (NASDAQ: EXOZ) is a pre-revenue biotechnology company that has built an AI-enhanced, cell-free biomanufacturing platform for producing complex natural compounds that are rare, unscalable, or economically inaccessible through conventional means. The company's core technology centers on "exozymes" — enzymes engineered through AI and bioengineering to operate in bioreactors without living cells, eliminating the scaling bottleneck that has constrained traditional synthetic biology. The platform was demonstrated at 100-liter pilot scale in March 2026 with partner Cayman Chemical, producing 535 grams of pharma-grade NCT (N-trans-caffeoyltyramine) at 99.6% purity and 99% feedstock conversion efficiency, achieving a 100x scale-up from initial 1-liter lab work.

The company's product portfolio is organized around multiple commercialization paths from this shared technology core. Flagship product NCT is positioned for both over-the-counter metabolic wellness (through wholly-owned subsidiary NCTx, focused on gut and liver health) and pharmaceutical development of analogs targeting metabolic diseases. Additional pipeline assets include non-intoxicating cannabinoids for therapeutic applications and santalene for the fragrance market. Supporting technology includes the BioClick enzyme engineering platform backed by a $300K NIH grant. The company was founded in 2019 as Invizyne Technologies, completed its $15 million NASDAQ IPO in November 2024, rebranded to eXoZymes in February 2025, and is a portfolio company of MDB Capital Holdings with an estimated valuation of approximately $30 million as of Q4 2025.

The business model is built on technology licensing and royalty arrangements with pharmaceutical and nutraceutical companies, supplemented by contract manufacturing partnerships (e.g., Cayman Chemical) and direct commercialization through NCTx. Go-to-market is enterprise-focused, led by a Chief Commercial Officer appointed in April 2025, with distribution through direct partnerships and contract manufacturer networks. Revenue has not yet commenced; FY2025 financials show operating expenses of $9.72 million against a $9.16 million net loss, with cash reserves of $3.04 million at year-end 2025 replenished by a $5.95 million public offering in June 2026.

eXoZymes firmographics

Firmographics
Name
eXoZymes
Legal name
eXoZymes Inc.
Website
https://exozymes.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
eXoZymes is a pre-revenue, NASDAQ-listed biotechnology company that uses AI-engineered cell-free exozymes to sustainably biomanufacture rare natural compounds, serving pharmaceutical, nutraceutical, and specialty chemical markets through its Exozymes Platform and NCTx subsidiary.
Ownership category
akta.pro rank

eXoZymes industry classification

Industry
Product category
Cell-free Biomanufacturing
NAICS
Other Basic Organic Chemical Manufacturing (32519)
SIC
Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYIMAMALAB
Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids)

Keywords

  • Cell-free biomanufacturing
  • Enzyme engineering platform
  • Biocatalytic production
  • Metabolic health compounds
  • Natural product manufacturing

Where eXoZymes is headquartered

Location

Headquarters

HQ city
Monrovia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

eXoZymes business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing: Pre-revenue company with business model focused on licensing its cell-free biomanufacturing platform technology to pharmaceutical, nutraceutical, and specialty chemical companies. Revenue expected through technology licensing and royalty arrangements.
  2. Product Commercialization: Direct commercialization of high-value natural products including NCT (N-trans-caffeoyltyramine) and non-intoxicating cannabinoids. Company has launched subsidiary NCTx to commercialize NCT for gut and liver health applications.
  3. Contract Manufacturing Services: Potential revenue from providing biomanufacturing services using its platform, demonstrated through successful pilot runs with partner Cayman Chemical producing pharma-grade NCT.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

eXoZymes product offering

Product offering

Core offering

eXoZymes operates a proprietary cell-free biomanufacturing platform that uses engineered exozymes—cell-free enzyme systems designed with the aid of its AI-driven BioClick tool—to manufacture rare, high-value natural compounds at commercial scale. The company's first commercial focus is NCT (N-trans-caffeoyltyramine), a metabolic-health compound sold through its NCTx subsidiary, with a broader pipeline spanning non-intoxicating cannabinoids, santalene, and other specialty molecules for pharmaceutical, nutraceutical, and specialty-chemical buyers.

Product overview

eXoZymes is an AI-enhanced, cell-free biomanufacturing platform company (formerly Invizyne Technologies). The company offers a unified platform of exozymes (AI-engineered enzymes operating outside living cells) that transforms rare, unscalable, or economically inaccessible chemistry into predictable, high-purity production. The product portfolio centers on the core Exozymes Platform for cell-free biomanufacturing, with flagship product NCT (N-trans-caffeoyltyramine) offered in both over-the-counter wellness and pharmaceutical formulations, supported by the NCTx subsidiary. Additional products include non-intoxicating cannabinoids and santalene in the pipeline, plus the BioClick enzyme engineering technology. The platform collapses development timelines, lowers capital intensity, and unlocks multiple commercialization paths across pharmaceutical, wellness, and industrial markets.

Differentiator

Problem solved

Functional benefit

Brands

  • NCTx: Subsidiary focused on gut and liver health products utilizing N-trans-caffeoyltyramine (NCT)
  • NCT
  • BioClick

Products and services

  • Exozymes Biomanufacturing Platform The company's core cell-free biomanufacturing platform that uses engineered exozymes and the AI-driven BioClick design tool to produce rare, high-value natural compounds for pharmaceutical, nutraceutical, and specialty-chemical customers.
  • NCT (N-trans-caffeoyltyramine) The company's flagship high-purity natural compound (N-trans-caffeoyltyramine) produced via the exozymes platform and positioned for metabolic-health applications, sold to nutraceutical and pharmaceutical customers.
  • NCTx (Gut/Liver Health Brand) Specialty subsidiary brand through which eXoZymes markets NCT-based ingredients and formulations for gut-health and liver-health nutraceutical products.
  • Non-intoxicating Cannabinoids (Pipeline) Pipeline of non-intoxicating cannabinoid molecules manufactured using the exozymes platform for pharmaceutical, wellness, and consumer-health buyers.
  • Santalene (Pipeline) Cell-free produced santalene, a valuable natural aroma chemical traditionally constrained by sandalwood supply, targeted at fragrance and flavor customers.
  • BioClick (Enzyme Engineering Platform) AI-enhanced enzyme engineering platform that designs and optimizes exozymes for the company's cell-free biomanufacturing processes, accelerating the design–build–test cycle for new biocatalysts.

Quantifiable outcome

  • 99% feedstock conversion efficiency at 100-liter pilot scale
  • +3 more outcomes

Companies that use eXoZymes

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

eXoZymes technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

eXoZymes partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Shell GameChanger Accelerator Powered by NLR (GCxN)coreStrategic or Co-development Partner · 7 May 2026Three-year collaboration (2023-2026) with Shell and U.S. Department of Energy's National Laboratory of the Rockies. Program provided technical guidance and nondilutive funding to advance eXoZymes' cell-free biomanufacturing platform toward commercial viability. Collaboration helped evaluate separation approaches and conduct technoeconomic and lifecycle analysis modeling. Company graduated from the program in 2026.
  • Cayman ChemicalcoreStrategic or Co-development Partner · 18 March 2026Independent partner Cayman Chemical successfully validated eXoZymes' cell-free biomanufacturing technology at pilot scale, scaling from 1-liter to 100-liter production run. Produced over 500 grams of pharma-grade NCT at 99.6% purity with 99% feedstock conversion. This was the first end-to-end run of eXoZymes' exozyme-based biomanufacturing process by a third party, demonstrating protocol transferability and operational robustness.
  • B2i DigitalminorGTM or Marketing Partner · 14 October 2025Partnership with B2i Digital to spotlight the company's cell-free, AI-guided enzyme platform for scalable biomanufacturing. B2i Digital provides marketing and visibility services to highlight the company's technology and commercial opportunities.
  • BioMADEcoreStrategic or Co-development Partner · 30 September 2025Two senior eXoZymes leaders elected to key governance roles within BioMADE, a federal manufacturing innovation institute focused on bioindustrial manufacturing. These appointments highlight eXoZymes' influence in advancing cell-free biomanufacturing and shaping the industry's future direction.
  • National Science Foundation (NSF) / Meta-PURE InitiativecoreStrategic or Co-development Partner · 26 June 2025Selected as core industry partner in $9.2 million NSF-funded project led by Georgia Tech aimed at advancing modular cell-free biomanufacturing. Company developing cell-free ATP-generating module and production module for santalene. Supports creation of sustainable chemical production systems.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

eXoZymes competitors and assessment

Company assessment

Direct peers

  • Codexis: Codexis engineers high-performance enzymes for pharmaceutical and sustainable chemistry applications. Most directly comparable peer given shared focus on AI/ML-guided enzyme engineering for complex molecule manufacturing and licensing-driven business model.
  • DMC Biotechnologies: DMC develops cell-free biomanufacturing processes using engineered enzyme cascades to produce chemicals and specialty products. Closely matches eXoZymes' core architectural choice (cell-free over cell-based).
  • Bota Bio: Bota Bio uses synthetic biology and enzyme engineering to manufacture sustainable ingredients and chemicals. Shares the AI-guided enzyme platform approach for producing high-value molecules at scale.
  • Arzeda: Arzeda uses AI-driven protein design to engineer enzymes for chemical and pharmaceutical manufacturing. Comparable on the AI+enzyme engineering intersection and specialty chemical pipeline focus.
  • LanzaTech: LanzaTech operates a biomanufacturing platform converting waste gases into fuels and chemicals via engineered microbes. Adjacent on biomanufacturing platform economics and sustainability-driven specialty chemicals.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo operates a large-scale synthetic biology platform serving pharmaceutical, industrial, and agricultural customers. While cell-based rather than cell-free, it competes for the same biomanufacturing platform customer mindshare and licensing budgets.
  • Novonesis (formerly Novozymes): Novonesis is a global enzyme and microbial solutions leader across industrial, food, and health markets. Represents the incumbent enzyme platform incumbent against which any newer platform like eXoZymes must compete for commercial partnerships.

Emerging players

  • Twist Bioscience: Twist Bioscience provides synthetic DNA and broader synthetic biology tools, increasingly moving into biopharma and synthetic biology-enabled product discovery. Comparable on the AI+synbio frontier and pipeline of novel molecules.
  • Zymergen (Ginkgo): Now part of Ginkgo, Zymergen historically combined automation, ML, and synthetic biology for specialty chemical and materials applications. Represents the historical template of a SynBio platform company attempting specialty chemical commercialization.
  • SyntheticGestalt: SyntheticGestalt applies AI to enzyme and pathway design for industrial biotechnology customers. Closely matches eXoZymes' positioning at the intersection of generative AI, enzyme engineering, and biomanufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

eXoZymes social profiles

Digital presence

eXoZymes financial estimates

Financial estimate

Revenue estimate

Valuation estimate

eXoZymes leadership team

Management profile

Number of profiles

Profiles7 records

eXoZymes subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

eXoZymes funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

eXoZymes M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eXoZymes

What does eXoZymes do?

eXoZymes operates a proprietary cell-free biomanufacturing platform that uses engineered exozymes—cell-free enzyme systems designed with the aid of its AI-driven BioClick tool—to manufacture rare, high-value natural compounds at commercial scale. The company's first commercial focus is NCT (N-trans-caffeoyltyramine), a metabolic-health compound sold through its NCTx subsidiary, with a broader pipeline spanning non-intoxicating cannabinoids, santalene, and other specialty molecules for pharmaceutical, nutraceutical, and specialty-chemical buyers.

Is eXoZymes a public or private company?

eXoZymes is a public company. It is classified as public and is currently operating.

When was eXoZymes founded?

eXoZymes was founded in 2019. It employs 11 to 50 people.

Where is eXoZymes based?

eXoZymes is headquartered in Monrovia, United States, in the North America region.

How does eXoZymes make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are product Commercialization and contract Manufacturing Services.

Who are eXoZymes's main competitors?

Direct peers on record are Codexis, DMC Biotechnologies, Bota Bio, Arzeda and LanzaTech. Broad incumbents are Ginkgo Bioworks and Novonesis (formerly Novozymes). Emerging players are Twist Bioscience, Zymergen (Ginkgo) and SyntheticGestalt.

Does eXoZymes have an API?

No public API is recorded for eXoZymes.

What industry is eXoZymes in?

eXoZymes's product category is Cell-free Biomanufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of IMAMALAB, Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids). Its NAICS code is 32519 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingVieweXoZymes Q3 2026 Earnings Call Is LiveeXoZymes' Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.The future of tradingExozymes Holds Annual Shareholder MeetingExozymes shareholders elected six directors and ratified RBSM LLP as independent auditor at the annual meeting on November 13, 2026. The meeting covered the fiscal year ending December 31, 2026.Quiver QuantitativeMDB Capital Holdings Provides Third Quarter 2026 Business Update and Highlights Progress Across Public Ventures, PatentVest, eXoZymes and Paulex Bio | MDBH Stock NewsMDB Capital Holdings issued a Q3 2026 business update, highlighting progress across Public Ventures, PatentVest, eXoZymes, and Paulex Bio. Fee income rose 96% to $4.2 million year-to-date, while operating expenses remained flat. The company will host a CEO-led webinar today to discuss developments.Stock TitanMDB Capital Holdings fee income rises 96% to $4.2MMDB Capital Holdings reported fee income of $4.2 million for nine months ended September 30, 2026, up 96% year-over-year. The company also highlighted progress on Public Ventures, PatentVest, eXoZymes, and Paulex Bio, with a CEO-led webinar scheduled today.TradingViewMDBH: Higher banking fees were outweighed by investment losses and a major eXoZymes impairmentMDB Capital Holdings reported a $32.5M net loss for the quarter, driven by $5.9M in investment-security losses and a $9.86M eXoZymes impairment, despite $9M in investment banking fees rising 54% year-over-year. Cash ended September at $8.3M, with $9.9M of working capital.TradingVieweXoZymes 3Q 2026: EPS ($0.24) — 10-Q SummaryeXoZymes reported a net loss of $2.24 million and diluted EPS of -$0.24 for Q3 2026, narrowing the loss 2.1% year-over-year. The company's 100-liter pilot converted 99% of feedstock at 99.6% purity, and it was selected for a DOE AI digital twin project. Management said working capital is insufficient for 12 months, raising substantial doubt about going concern.Business & FinancialBiotech Entrepreneur Michael Heltzen Tells Tomorrow, Today How Enzymes Can Work Outside Living CellsMichael Heltzen, CEO of eXoZymes, discussed his company's cell-free enzyme systems in a Tomorrow, Today episode. He explained that cells resist being forced into chemical factories, and his company engineers enzymes to produce natural molecules outside living cells. He also advised that human skills like empathy and teamwork remain uniquely valuable in an AI economy.International Business TimesWhy eXoZymes Is Standing Out to Investor James TissotJames Tissot sees eXoZymes as a biotech with a platform-based investment case, citing Cayman Chemical's third-party validation of its NCT process. The pilot achieved 99% conversion and 90% yield, with Curia selected for commercial scale-up targeting a 2027 launch. Tissot argues repeatability across the portfolio could strengthen shareholder value.FinancialContent Business PageeXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower ResearcheXoZymes CEO Michael Heltzen will host a fireside chat with Water Tower Research on October 22, 2026, discussing commercialization of its cell-free biomanufacturing platform. The chat will cover NCT, a nutraceutical molecule, and potential catalysts over the next 12 months.Stock TitaneXoZymes CEO to Discuss NCT at Oct. 22 Fireside ChateXoZymes CEO Michael Heltzen will join a Water Tower Research fireside chat on October 22, 2026, to discuss commercializing NCT, a naturally occurring molecule for nutraceuticals. The chat will cover manufacturing economics, scale-up with Curia, and potential revenue streams through NCTx. Heltzen also outlined a platform for additional molecules, including rare cannabinoids.